CSCIFCOSCIENS Biopharma Inc.vs its industry peers
A metric-by-metric comparison of COSCIENS Biopharma Inc. against Perfumes, Cosmetics & Other Toilet Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSCIFEsta | — | — | — | — | -21.8%#8 | 32.3%#3 | -142.5%#7 | -269.6%#6 | — | — | — | — |
| UG | $33M#3 | — | 2.8x#3 | 3.1x#3 | -13.4%#7 | -35.2%#5 | 21.3%#1 | 18.1%#2 | — | — | -3.1%#3 | 8.4%#1 |
| CABR | $14M#4 | — | — | 3247.0x#5 | — | -313.7%#8 | -140807.2%#9 | — | — | — | — | — |
| BNKK | $12M#5 | — | 0.4x#1 | 5.7x#4 | 201.6%#2 | -38.0%#6 | -3138.4%#8 | -247.7%#5 | — | — | -86.6%#6 | — |
| YCBD | $5M#6 | — | 0.6x#2 | 0.3x#1 | -1.5%#5 | 44.8%#2 | -11.3%#5 | -24.9%#4 | — | — | -3.3%#4 | — |
| DQWS | — | — | — | — | -6.2%#6 | -445.9%#9 | -0.0%#4 | — | — | — | — | — |
| EL | $34.9B#2 | 192.7x#2 | 8.7x#4 | 2.3x#2 | 5.0%#4 | 116.1%#1 | 5.2%#3 | 4.6%#3 | 8.1%#1 | — | 11.3%#1 | 1.5%#2 |
| HLN | $83.9B#1 | — | — | — | — | — | — | — | — | — | 2.3%#2 | — |
| KARX | — | — | — | — | 1665.6%#1 | -92.7%#7 | -19.8%#6 | — | — | — | — | — |
| ODD | — | 10.2x#1 | — | — | 25.2%#3 | 9.1%#4 | 14.7%#2 | 27.9%#1 | — | — | -70.8%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2844). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-22.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice